PTC Therapeutics Inc (PTCT)

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 17, 2026 4:30 PM
PR Newswire (US) WARREN, N.J., June 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2026, the company approved non-statutory stock options to purchase an aggregate of 10,050 shares of its common stock and 11,870 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 18 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.The inducement grants were approved by PTC's Compensation Committee on June 11, 2026, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).All stock option awards have an exercise price of $74.71 per share, the closing price of PTC's common stock on June 11, 2026, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. The RSUs each will vest over four years with 25% of the original number of shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, subject to the employee's continued service with the company through the applicable vesting dates.About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Instagram and Facebook.For more information please contact:Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri @chemical imbalance
jclemente@ptcbio.com View original content:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302803422.htmlSOURCE PTC Therapeutics, Inc. Original: PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible NotesJune 15, 2026 11:14 PM
PR Newswire (US) – Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 convertible notes prior to or at maturity –– Offering made at 0% interest with conversion price of $107.48, a 40% premium over the closing price on June 15, 2026 –WARREN, N.J., June 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the pricing of $500.0 million aggregate principal amount of 0% Convertible Senior Notes due 2031 (the "Notes") in a private placement (the "Offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). PTC also granted the initial purchasers an option to purchase, within the 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $50.0 million aggregate principal amount of Notes from PTC. The sale of the Notes is expected to close on June 18, 2026, subject to the satisfaction of customary closing conditions.The Notes will be general senior unsecured obligations of PTC, and will not bear regular interest and the principal amount of the Notes will not accrete. The Notes will mature on June 15, 2031, unless earlier converted, repurchased or redeemed.PTC estimates that the net proceeds from the Offering will be approximately $486.8 million (or approximately $535.5 million if the initial purchasers exercise their option to purchase additional Notes in full), after deducting the initial purchasers' discounts and commissions and estimated offering expenses payable by PTC.PTC expects to use approximately $328.8 million of the net proceeds from the Offering to repurchase for cash $222.0 million in aggregate principal amount of its 1.5% Convertible Senior Notes due 2026 (the "2026 Notes") pursuant to the concurrent note repurchase transactions described below. Given the dynamics of the Offering, PTC will not use any proceeds of the Offering to repurchase, concurrently with the Offering, shares of its common stock sold short by initial investors in the Offering. The remaining net proceeds from the Offering will be used for general corporate purposes, which may include additional repurchases of the 2026 Notes from time to time following the Offering and the repayment or retirement of any remaining 2026 Notes at maturity.Prior to the close of business on the business day immediately preceding March 15, 2031, holders will have the right to convert their Notes only upon the satisfaction of specified conditions and during certain periods. On or after March 15, 2031 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes at any time. Upon conversion, PTC will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election.The conversion rate for the Notes will initially be 9.3042 shares of PTC's common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $107.48 per share of PTC's common stock). The initial conversion price represents a premium of approximately 40% over the closing price of $76.77 per share of PTC's common stock on the Nasdaq Global Select Market on June 15, 2026.PTC may not redeem the Notes prior to June 20, 2029. On or after June 20, 2029, PTC may redeem for cash all or any portion of the Notes, at its option, if the last reported sale price of PTC's common stock has been at least 130% of the conversion price for the Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which PTC provides written notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid special interest, if any, to, but excluding, the redemption date. No sinking fund is provided for the Notes, which means PTC is not required to redeem or retire the Notes periodically.If PTC undergoes a "fundamental change" (as defined in the indenture that will govern the Notes), then, subject to certain conditions and limited exceptions, holders may require PTC to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid special interest, if any, to, but excluding, the fundamental change repurchase date. In addition, following certain corporate events that occur prior to the maturity date or if PTC delivers a notice of redemption, PTC will, in certain circumstances, increase the conversion rate for a holder who elects to convert its Notes in connection with such a corporate event or notice of redemption, as the case may be.Concurrently with the pricing of the Notes in the Offering, PTC entered into private negotiated transactions with certain holders of the 2026 Notes to repurchase for a total repurchase cost (including accrued and unpaid interest) of approximately $328.8 million in cash $222.0 million in aggregate principal amount of the 2026 Notes on terms negotiated with each holder. This press release is not a notice of redemption or an offer to repurchase the 2026 Notes, and the Offering of the Notes is not contingent upon the repurchase of any of the 2026 Notes.In connection with any repurchase of the 2026 Notes, PTC expects that holders of the 2026 Notes who agreed to have their 2026 Notes repurchased may enter into or unwind various derivatives with respect to PTC's common stock and/or purchase shares of PTC's common stock concurrently with or shortly after the pricing of the 2026 Notes. In particular, PTC expects that certain holders of the 2026 Notes employ a convertible arbitrage strategy with respect to the 2026 Notes and have a short position with respect to PTC's common stock that they will close out through purchases of PTC's common stock and/or the unwinding of various derivatives with respect to PTC's common stock, as the case may be, in connection with PTC's repurchase of the 2026 Notes. This activity could increase (or reduce the size of any decrease in) the market price of PTC's common stock, which may also affect the trading price of the Notes at that time. This activity may have affected the market price of PTC's common stock prior to, concurrently with or shortly after the pricing of the Notes, and could result in a higher effective conversion price of the Notes. PTC cannot predict the magnitude of such market activity or the overall effect it will have on the price of the Notes or PTC's common stock.The Notes were only offered by means of a private offering memorandum. The offer and sale of the Notes and any shares of PTC's common stock issuable upon conversion of the Notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the Notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the Notes or any shares of PTC's common stock issuable upon conversion of the Notes, nor will there be any sale of the Notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful. About PTC Therapeutics, Inc. 
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders.For more information please contact:Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri @chemical imbalance
jclemente@ptcbio.comCautionary Note Regarding Forward-Looking Statements:The press release contains information about future expectations, plans and prospects of PTC's management that constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements with respect to PTC's expectations to complete the Offering of the Notes, its use of proceeds from the Offering and the effect of the concurrent note repurchase. There can be no assurance that PTC will be able to complete the notes offering on the anticipated terms, or at all. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, the terms of the Notes and the Offering, risks and uncertainties related to whether or not PTC will consummate the Offering, the impact of general economic, industry, market or political conditions and other factors that are discussed in PTC's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents periodically filed with the Securities and Exchange Commission.In addition, the statements in this press release represent PTC's expectations and beliefs as of the date of this press release. PTC anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while PTC may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing PTC's expectations or beliefs as of any date subsequent to the date of this press release. View original content:https://www.prnewswire.com/news-releases/ptc-therapeutics-announces-pricing-of-convertible-notes-offering-to-refinance-2026-convertible-notes-302801013.htmlSOURCE PTC Therapeutics, Inc. Original: PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes

PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible NotesJune 15, 2026 7:00 AM
PR Newswire (US) – Proceeds to be used to repurchase or repay 2026 convertible notes prior to or at maturity – – Offering to include buyback of common stock –WARREN, N.J., June 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2031 (the "Notes") in a private placement (the "Offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). PTC intends to grant the initial purchasers an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to $50.0 million of additional Notes. The Notes will be general senior unsecured obligations of PTC and will accrue interest payable semiannually in arrears. The Notes will mature on June 15, 2031, unless earlier converted, repurchased or redeemed. Upon conversion, PTC will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at PTC's election. The interest rate, initial conversion rate and other terms of the Notes will be determined at the time of pricing of the Offering.PTC expects to use net proceeds from the Offering for repurchases of a portion of its 1.5% Convertible Senior Notes due 2026 (the "2026 Notes") concurrently with the Offering, and for the repayment or retirement of any remaining 2026 Notes at maturity. PTC also expects to repurchase shares of common stock in an amount of approximately $50.0 million, through privately negotiated transactions effected concurrently with the Offering, although the amount of its common stock that PTC actually repurchases may be more or less than $50 million. Any remaining net proceeds from the Offering will be used for general corporate purposes, which may include additional repurchases of the 2026 Notes from time to time following the Offering.In connection with the concurrent share repurchase described above, PTC expects to repurchase shares of its common stock sold short by initial investors in the Offering in privately negotiated transactions effected with or through one of the initial purchasers or its affiliate at a purchase price per share expected to be equal to the closing price per share of PTC's common stock on the pricing date of the Offering. These repurchases could increase (or reduce the size of any decrease in) the market price of PTC's common stock or the Notes. This activity could affect the market price of PTC's common stock prior to, concurrently with or shortly after the pricing of the Notes, and could result in a higher effective conversion price for the Notes.PTC may repurchase for cash a portion of the 2026 Notes concurrently with the Offering pursuant to one or more separate and individually negotiated transactions with one or more holders of the 2026 Notes (each, a "concurrent note repurchase transaction"). The terms of each concurrent note repurchase transaction will depend on a variety of factors, including the market price of PTC's common stock and the trading price of the 2026 Notes at the time of the repurchase, if any. No assurance can be given as to how much, if any, of the 2026 Notes will be repurchased or the terms on which they will be repurchased. This press release is not a notice of redemption or an offer to repurchase the 2026 Notes, and the Offering of the Notes is not contingent upon the repurchase of any of the 2026 Notes.In connection with any repurchase of the 2026 Notes, PTC expects that holders of the 2026 Notes who agree to have their 2026 Notes repurchased may enter into or unwind various derivatives with respect to PTC's common stock and/or purchase shares of PTC's common stock concurrently with or shortly after the pricing of the Notes. In particular, PTC expects that many holders of the 2026 Notes employ a convertible arbitrage strategy with respect to the 2026 Notes and have a short position with respect to PTC's common stock that they would close out through purchases of PTC's common stock and/or the unwinding of various derivatives with respect to PTC's common stock, as the case may be, in connection with PTC's repurchase of the 2026 Notes, if any. This activity could increase (or reduce the size of any decrease in) the market price of PTC's common stock, which may also affect the trading price of the Notes at that time and could result in a higher effective conversion price of the Notes. PTC cannot predict the magnitude of such market activity or the overall effect it will have on the price of the Notes or PTC's common stock.The offer of Notes will be made only by means of a private offering memorandum. The offer and sale of the Notes and any shares of PTC's common stock issuable upon conversion of the Notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the Notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the Notes or any shares of PTC's common stock issuable upon conversion of the Notes, nor will there be any sale of the Notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful. About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders.For more information please contact:Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri @chemical imbalance
jclemente@ptcbio.com Cautionary Note Regarding Forward-Looking Statements:
The press release contains information about future expectations, plans and prospects of PTC's management that constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements with respect to PTC's expectations to complete the proposed offering of the Notes, the terms of the Offering, its use of proceeds from the Offering, expectations regarding the concurrent share and note repurchases and the effect of the potential concurrent share and note repurchases. There can be no assurance that PTC will be able to complete the proposed notes offering on the anticipated terms, or at all. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, the terms of the Notes and the Offering, risks and uncertainties related to whether or not PTC will consummate the Offering, the impact of general economic, industry, market or political conditions and other factors that are discussed in PTC's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents periodically filed with the Securities and Exchange Commission.In addition, the statements in this press release represent PTC's expectations and beliefs as of the date of this press release. PTC anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while PTC may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing PTC's expectations or beliefs as of any date subsequent to the date of this press release. View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-announces-proposed-convertible-notes-offering-to-refinance-2026-convertible-notes-302800228.htmlSOURCE PTC Therapeutics, Inc. Original: PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes

PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of VotoplamApril 28, 2026 4:05 PM
PR Newswire (US)

- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose -- Continued evidence of favorable safety profile - - Novartis initiated global Phase 3 INVEST-HD study of votoplam -- PTC will host a conference call to discuss results today, April 28, at 4:30 pm ET - WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study, with favorable dose-dependent effects on disease progression for Stage 2 Huntington's disease (HD) patients following 24 months of votoplam treatment compared to an external natural history cohort. "These results give us confidence in the potential for votoplam to deliver long-term meaningful effect on slowing Huntington's disease progression," said Matthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics. "In particular, the evidence of dose-dependent slowing of progression on the cUHDRS disease rating scale in the Stage 2 study participants supports the Novartis-initiated Phase 3 INVEST-HD study. We look forward to continuing to review the data and aligning on potential regulatory interactions based on the results with our partner Novartis."The PIVOT-HD study was a 12-month placebo-controlled study of two dose levels of votoplam in participants with Stage 2 and Stage 3 HD. The study met the primary endpoint of blood Huntingtin (HTT) protein lowering at 12 weeks, with persistent dose-dependent lowering at Month 12. PIVOT-HD participants then enrolled in the PIVOT-HD extension study in which those originally randomized to receive 5 mg or 10 mg of votoplam remained on those dose levels. Participants initially randomized to receive placebo were randomized to receive 5 mg or 10 mg. All participants and investigators remain blinded to initial PIVOT-HD treatment assignment. The objectives of the long-term extension study are to assess the safety and efficacy of long-term votoplam treatment. In the interim analysis following 24 months of votoplam treatment, there was evidence of dose-dependent benefit in slowing progression on the Composite Unified Huntington's Disease Rating Scale (cUHDRS) relative to a propensity weighted natural history cohort in Stage 2 participants, with 52% and 28% slowing for 10 mg and 5 mg participants, respectively. Signals of favorable treatment effects relative to natural history were recorded across the cUHDRS subscales for the 10 mg cohort. In addition, there were no treatment-related neurofilament light chain protein (NfL) increases and mean NfL levels remained below baseline at 24 months for both high and low dose cohorts – in contrast to the reported natural history that NfL levels increase over time in individuals with HD. In Stage 3 participants, potential signals of slowing of progression were observed at 24 months. Importantly, the safety data at Month 24 for both dose levels and both stages were consistent with the previously established evidence of favorable safety. Novartis announced their initiation of the global Phase 3 INVEST-HD study on their First Quarter Earnings Call earlier today. This placebo-controlled study will enroll approximately 770 individuals with early-stage HD who will be randomized 3:2 to receive votoplam 10 mg or placebo. The primary endpoint will be the change from baseline up to month 36 in the cUHDRS. The INVEST-HD study is sponsored and funded by Novartis. Novartis and PTC will continue to review the data and discuss potential next steps including regulatory interactions.Conference Call and Webcast Details:
PTC will hold a conference call at 4:30 pm ET today to discuss this news. The webcast conference call can be accessed on the Investors section of the PTC website at https://ir.ptcbio.com/events-presentations. To participate via phone, please register in advance here to receive dial-in details. A replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for 30 days following the call.About PIVOT-HD
PIVOT-HD was designed as a 12-month placebo-controlled trial to assess pharmacodynamic effect and safety of votoplam at two dose levels, 5 mg and 10 mg, relative to placebo. Initially, the study included only Stage 2 patients. A Stage 3 cohort of similar size was subsequently added to help identify the best study population for future studies. The primary endpoints of PIVOT-HD were total blood Huntingtin (HTT) lowering at 12 weeks and safety events. Secondary endpoints included 12-month blood HTT levels, and other blood-and central nervous system (CNS) biomarkers as well as changes in Composite Unified Huntington's Disease Rating Scale (cUHDRS).Following 12 months, patients were eligible to enroll in a long-term extension study in which all subjects would receive votoplam. Those originally randomized to 5 mg and 10 mg would continue at that dose level; those initially randomized to placebo would be randomized 1:1 to 5 mg or 10 mg. All subjects and investigators remain blinded to initial treatment assignment.About Votoplam
Votoplam (formerly PTC518) is a small molecule splicing modifier that acts via a unique mechanism to promote the inclusion of a novel pseudoexon containing a premature termination codon, thus triggering Huntingtin (HTT) mRNA degradation and subsequent reduction in HTT protein levels. Votoplam was discovered from PTC's validated splicing platform, following the successful discovery and development of Evrysdi® (risdiplam) for spinal muscular atrophy (SMA). Votoplam was partnered with Novartis in December 2024. Following the completion of the PIVOT-HD clinical trial, Novartis assumed responsibility for votoplam's development, manufacturing and commercialization.About Huntington's Disease
Huntington's disease (HD) is a fatal, hereditary, genetic disorder of the central nervous system.1 It is caused by a defective gene. This gene produces a protein, called Huntingtin (HTT), which is involved in the functioning of the nerve cells in the brain (neurons). When the gene is defective, it produces an abnormal (or mutated) HTT protein that is toxic and causes neuron damage and neuron death.2  HD usually presents in people who are in their 30s or 40s. Symptoms can present earlier in life, and this is called Juvenile HD.2,3 There are also cases of infantile HD, when symptoms develop in children who are younger than 10 years old.2 While symptoms vary from person to person, the disease primarily affects the brain and results in abnormal movements, difficulties with speech, swallowing and walking, as well as a number of other symptoms including behavioral, cognitive and motor symptoms.4,5 While there are therapies approved for specific disease symptoms, currently, there is no cure for HD and there are no approved drugs that delay the onset or slow disease progression.About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Instagram and Facebook.For More Information:Investors:
Ellen Cavaleri
+1 (615) 618-6228
ecavaleri @chemical imbalance
jclemente@ptcbio.com Forward-Looking Statement:
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historic fact, are forward-looking statements, including statements with respect to the future expectations, plans and prospects for PTC, PTC's strategy, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses, and other matters, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to PTC's license and collaboration agreement with Novartis Pharmaceuticals Corporation for votoplam for the treatment of Huntington's disease including its right to receive development, regulatory and sales milestones, profit sharing and royalty payments from Novartis, the design and expected timing of clinical trials and studies, the availability of data, and regulatory submissions and responses, including potential accelerated approval; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC's most recent Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory or prove to be commercially successful.The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.References:World Health Organization, 2020. 8A01.10 Huntington disease. Available at: https://icd.who.int/browse10/2019/en#/G10. Accessed October 2021.Gatto EM, González Rojas N, Persi G, et al. Clin Parkinsonism Rel Disord 2020;3:100056.Tabrizi SJ, Flower MD, Ross CA, et al. Nat Rev Neurol 2020;16(10):529–546.Roos RAC. Orphanet J Rare Dis 2010; 5:40.Kirkwood SC, Su JL, Conneally P, et al. Arch Neurol 2001;58(2):273–278.



View original content:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-positive-topline-results-from-month-24-interim-analysis-of-pivot-hd-extension-study-of-votoplam-302756238.htmlSOURCE PTC Therapeutics, Inc.

Original: PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension StudyApril 28, 2026 9:28 AM
PR Newswire (US)

WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call today, April 28 at 4:30 p.m. ET to share results from the 24-month interim analysis of the PIVOT-HD long-term extension study of votoplam. PTC's partner Novartis stated on its quarterly earnings call today that long-term extension data are supportive of the now-initiated Novartis Phase 3 INVEST-HD study and Novartis and PTC will assess potential best next steps for the program including further actions with FDA.To access the live webcast, please visit the "Events & Presentations" page within the Investors section of the PTC website. A replay of the webcast will be available on the PTC website for 30 days following the event. To participate via phone, please register in advance here to receive dial-in details.About PIVOT-HD
PIVOT-HD was designed as a 12-month placebo-controlled trial to assess pharmacodynamic effect and safety of votoplam at two dose levels--5mg and 10mg, relative to placebo. Initially, the study included only Stage 2 patients. A Stage 3 cohort of similar size was subsequently added to help identify the best study population for future studies. The primary endpoints of PIVOT-HD were total blood Huntingtin (HTT) lowering at 12 weeks and safety events. Secondary endpoints included 12-month blood HTT levels, and other blood-and central nervous system (CNS) biomarkers as well as changes in Composite Unified Huntington's Disease Rating Scale (cUHDRS).Following 12 months, patients were eligible to enroll in a long-term extension study in which all subjects would receive votoplam. Those originally randomized to 5mg and 10mg would continue at that dose level; those initially randomized to placebo would be randomized 1:1 to 5mg or 10mg. All subjects and investigators remain blinded to initial treatment assignment.About Votoplam
Votoplam (formerly PTC518) is a small molecule splicing modifier that acts via a unique mechanism to promote the inclusion of a novel pseudoexon containing a premature termination codon, thus triggering Huntingtin (HTT) mRNA degradation and subsequent reduction in HTT protein levels. Votoplam was discovered from PTC's validated splicing platform, following the successful discovery and development of Evrysdi® (risdiplam) for spinal muscular atrophy (SMA). Votoplam was partnered with Novartis in December 2024. Following the completion of the PIVOT-HD clinical trial, Novartis assumed responsibility for votoplam's development, manufacturing and commercialization.About Huntington's Disease
Huntington's disease (HD) is a fatal, hereditary, genetic disorder of the central nervous system.1 It is caused by a defective gene. This gene produces a protein, called Huntingtin (HTT), which is involved in the functioning of the nerve cells in the brain (neurons). When the gene is defective, it produces an abnormal (or mutated) HTT protein that is toxic and causes neuron damage and neuron death.2 HD usually presents in people who are in their 30s or 40s. Symptoms can present earlier in life, and this is called Juvenile HD.2,3 There are also cases of infantile HD, when symptoms develop in children who are younger than 10 years old.2 While symptoms vary from person to person, the disease primarily affects the brain and results in abnormal movements, difficulties with speech, swallowing and walking, as well as a number of other symptoms including behavioral, cognitive and motor symptoms.4,5 While there are therapies approved for specific disease symptoms, currently, there is no cure for HD and there are no approved drugs that delay the onset or slow disease progression.About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Instagram and Facebook.For more information, please contact:Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri @chemical imbalance
jclemente@ptcbio.comForward-Looking Statement:
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historic fact, are forward-looking statements, including statements with respect to the future expectations, plans and prospects for PTC, PTC's strategy, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses, and other matters, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to PTC's license and collaboration agreement with Novartis Pharmaceuticals Corporation for votoplam for the treatment of Huntington's disease including its right to receive development, regulatory and sales milestones, profit sharing and royalty payments from Novartis, the design and expected timing of clinical trials and studies, the availability of data, and regulatory submissions and responses, including potential accelerated approval; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC's most recent Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory or prove to be commercially successful. The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law. References:World Health Organization, 2020. 8A01.10 Huntington disease. Available at: https://icd.who.int/browse10/2019/en#/G10. Accessed October 2021.Gatto EM, González Rojas N, Persi G, et al. Clin Parkinsonism Rel Disord 2020;3:100056.Tabrizi SJ, Flower MD, Ross CA, et al. Nat Rev Neurol 2020;16(10):529–546.Roos RAC. Orphanet J Rare Dis 2010; 5:40.Kirkwood SC, Su JL, Conneally P, et al. Arch Neurol 2001;58(2):273–278.



View original content:https://www.prnewswire.com/news-releases/ptc-therapeutics-to-report-results-from-pivot-hd-long-term-extension-study-302755766.htmlSOURCE PTC Therapeutics, Inc.

Original: PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 17, 2026 4:30 PM
PR Newswire (US)

WARREN, N.J., April 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2026, the company approved non-statutory stock options to purchase an aggregate of 1,155 shares of its common stock and 925 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to a new non-executive employee. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hire's employment compensation.







The inducement grant was approved by PTC's Compensation Committee on April 13, 2026, and is being made as an inducement material to the employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).All stock option awards have an exercise price of $70.42 per share, the closing price of PTC's common stock on April 13, 2026, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the vesting dates. The RSUs each will vest over four years, with 25% of the original number of shares vesting on each annual anniversary of the employee's new hire date until fully vested, subject to the employee's continued service with the company through the vesting dates.ABOUT PTC THERAPEUTICS, INC.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Instagram and Facebook.For more information, please contact:Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri @chemical imbalance
jclemente@ptcbio.com



View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302744354.htmlSOURCE PTC Therapeutics, Inc.

Original: PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of DirectorsMarch 25, 2026 8:30 AM
PR Newswire (US)

WARREN, N.J., March 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the appointment of Jessica Chutter to its Board of Directors. Ms. Chutter is a highly accomplished biotechnology investment banker with an extensive list of achievements over her long tenure at Morgan Stanley, including building and leading the bank's biotechnology franchise. "I have closely followed Jessica's illustrious career, and I am proud to welcome her to PTC's Board of Directors," said Michael Schmertzler, Chairman of the Board of Directors. "Jessica will play an integral role as the Board continues to work with the management team on charting the company's next stage of growth."Ms. Chutter recently retired as Managing Director and Chair of Biotechnology Investment Banking of Morgan Stanley after a distinguished career spanning over 40 years. She helped build the biotechnology banking practice at Morgan Stanley and is widely considered a pioneer in establishing the field of biotechnology investment banking. During her tenure at Morgan Stanley, Ms. Chutter was involved in approximately $80 billion of capital raising and $85 billion of strategic transactions. Ms. Chutter earned a BA in Commerce/Economics from McGill University and an MBA from Harvard University."We look forward to Jessica's contributions as we continue to build the PTC of the future," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. "Jessica was a trusted advisor to PTC during her time at Morgan Stanley and her broad vision, extensive biotech experience and track record of successful company building will make her a valued Board member.""I have been impressed with the transformation of PTC over the past few years into a strong and execution-oriented biotech company well positioned for future success," said Ms. Chutter. "I look forward to working with Matt, Michael, and the rest of the PTC Board at this important time in the company's growth."About PTC Therapeutics, Inc. 
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Instagram and Facebook.For more information, please contact:Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri @chemical imbalance
jclemente@ptcbio.comForward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC; PTC's strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; and the factors discussed in the "Risk Factors" section of PTC's most recent Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful.The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.



View original content:https://www.prnewswire.com/news-releases/ptc-therapeutics-appoints-biotech-banking-pioneer-jessica-chutter-to-board-of-directors-302724358.htmlSOURCE PTC Therapeutics, Inc.

Original: PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 13, 2026 4:30 PM
PR Newswire (US)

WARREN, N.J., March 13, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 10, 2026, the company approved non-statutory stock options to purchase an aggregate of 14,550 shares of its common stock and 17,515 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 18 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.







The inducement grants were approved by PTC's Compensation Committee on March 10, 2026, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).All stock option awards have an exercise price of $68.56 per share, the closing price of PTC's common stock on March 10, 2026, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. The RSUs each will vest over four years, with 25% of the original number of shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, subject to the employee's continued service with the company through the applicable vesting dates.About PTC Therapeutics, Inc. 
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Instagram and Facebook.For more information, please contact:Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri @chemical imbalance
jclemente@ptcbio.com



View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302712038.htmlSOURCE PTC Therapeutics, Inc.

Original: PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics Provides Regulatory Update on Translarna™February 12, 2026 5:00 PM
PR Newswire (US)

WARREN, N.J., Feb. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application (NDA) resubmission for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (DMD) following U.S. Food and Drug Administration (FDA) feedback on the application review."FDA shared that based on its review to date, the data in the NDA submission are unlikely to meet the Agency's threshold of substantial evidence of effectiveness to support approval of Translarna. We have therefore made the decision to withdraw the NDA submission," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. "We have worked tirelessly for over two decades to develop a safe and effective therapy for boys and young men affected by nonsense mutation DMD in the U.S. and are disappointed that FDA approval cannot be achieved."About Translarna™ (ataluren)
Translarna (ataluren), is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein. The resulting disorder is determined by which protein cannot be expressed in its entirety and is no longer functional, such as dystrophin in Duchenne.About Duchenne Muscular Dystrophy (Duchenne)
Primarily affecting males, Duchenne is a rare and fatal genetic disorder that results in progressive muscle weakness from early childhood and leads to premature death in the mid-20s due to heart and respiratory failure. It is a progressive muscle disorder caused by the lack of functional dystrophin protein. Dystrophin is critical to the structural stability of all muscles, including skeletal, diaphragm, and heart muscles. Patients with Duchenne can lose the ability to walk (loss of ambulation) as early as 10 years old, followed by loss of the use of their arms. Duchenne patients subsequently experience life-threatening lung complications, requiring the need for ventilation support, and heart complications in their late teens and 20s.About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow on Facebook, X, and LinkedIn.For More Information: Investors: Ellen Cavaleri
+1 (615) 618-6228
ecavaleri @chemical imbalance
jclemente@ptcbio.comForward-Looking Statement
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses, commercialization and other matters with respect to its products and product candidates; PTC's strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third-party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; PTC's ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in geographies in which it has been approved and the effect of the European Commission's adoption of the negative opinion from the Committee for Medicinal Products for Human Use (CHMP) on Translarna and the withdrawal of the U.S. Translarna NDA on other regulatory bodies; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; and the factors discussed in the "Risk Factors" section of PTC's most recent Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna.The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.



View original content:https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-regulatory-update-on-translarna-302686879.htmlSOURCE PTC Therapeutics, Inc.

Original: PTC Therapeutics Provides Regulatory Update on Translarna™

PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026February 5, 2026 8:00 AM
PR Newswire (US)

WARREN, N.J., Feb. 5, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its fourth quarter and full year 2025 financial results and provide an update on the company's business and outlook on Thursday, Feb. 19, 2026, at 4:30 p.m. ET.







To access the call by phone, please click here to register and you will be provided with dial-in details. The webcast conference call can be accessed on the Investors section of the PTC website at https://ir.ptcbio.com/events-presentations. A replay of the call will be archived on the company's website for 30 days.About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. PTC's ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. To learn more about PTC, please visit us at www.ptcbio.com and follow us on LinkedIn, X, Facebook, and Instagram.For more information, please contact:Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri @chemical imbalance
jclemente@ptcbio.com



View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-on-thursday-feb-19-2026-302679246.htmlSOURCE PTC Therapeutics, Inc.

Original: PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026

PTCT over $20

Power hour PTCT let go

Great news out $PTCT https://ir.ptcbio.com/news-releases/news-release-details/spinal-muscular-atrophy-sma-foundation-and-ptc-therapeutics

Lol at the ask wild ride wee weee

Wow what a day

Wow already jumping up

Hello $PTCT

Anything pushing this higher next year?
Debt is already a tad high, when will another
offering be needed?

News: $PTCT PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna(TM) (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy

SOUTH PLAINFIELD, N.J. , Oct. 4, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that data from STRIDE,* the first international registry for patients with Duchenne muscular dystrophy due to a nonsense mutation receiving Translarnaä (ataluren), de...

In case you are interested PTCT - PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna(TM) (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy

News: $PTCT PTC Provides Update on Translarna(TM) (ataluren) Application for Label Expansion

SOUTH PLAINFIELD, N.J. , June 28, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has completed their review of a proposed indication extension of Translar...

Read the whole news https://marketwirenews.com/news-releases/ptc-provides-update-on-translarna-tm-ataluren-application-for-l-8429210.html

GREAT POINT PARTNERS LLC has filed a new 13G, reporting 5.24% ownership in $PTCT - https://fintel.io/soh/us/ptct/great-point-partners-llc and https://fintel.io/i/great-point-partners-llc

Closing in on a charting target - anyone want to comment on the pipeline?

That's pretty significant. It was a no-brainer after they bought Emflaza. The market reaction was irrationally negative. I didn't think PTCT would move this quickly back up, but I'm glad I got back in when I did.
glty

Complete Pharma Holdings II, LLC has filed a new 13G, reporting 16.2% ownership in $PTCT - https://fintel.io/so/us/ptct

RTW INVESTMENTS, LLC has filed a new 13G, reporting 5.2% ownership in $PTCT - https://fintel.io/so/us/ptct

PTCT bullish 8.64









normal chart




log chart

Here’s What Happened To Karyopharm Therapeutics Inc and PTC Therapeutics, Inc. https://marketexclusive.com/heres-what-happened-to/78614/?icd1

Bummer. I dumped my remaining shares pre-market. Possibility I'll buy back at some point, but I think PTCT has a while before anything positive happens.
Good luck all.

Credit Suisse Says PTC Therapeutics Could Trade Up Between $80 And $100

https://finance.yahoo.com/news/credit-suisse-says-ptc-therapeutics-154545551.html

Marathon getting $89k for DMD drug. Administration pushing for lower drug prices, so competition in this space would be good in that respect. PTC will be pushing the FDA on this.
Dip seems good for investors. I don't see this as bad news for PTC. Just the opposite. I realize the patients who potentially benefit from Marathon's drug and Ataluren drug are initially different. Interesting that SRPT was up on the news.

http://www.wsj.com/amp/articles/marathon-pharmaceuticals-to-charge-89-000-for-muscular-dystrophy-drug-1486738267

http://wincountry.com/news/articles/2017/feb/09/fda-approves-marathon-pharmaceuticals-dmd-drug/

Orphan drug designation:

http://www.prnewswire.com/news-releases/rg7916-granted-orphan-drug-designation-in-the-us-for-the-treatment-of-spinal-muscular-atrophy-300386964.html

I would expect the premarket volume to be higher than it is.

PTC Therapeutics announces its JV w/ Roche (RHHBY) and the SMA Foundation initiated a clinical study (FIREFISH) in infants with Type I SMA

FIREFISH is a two-part study.
•Part one is an open-label, dose escalation study in at least 8 infants for a minimum of 4 weeks. ?The primary objective of part one is to assess the safety profile of RG7916 in infants and determine the dose for part two.

•Part two is an open-label, single-arm study in !40 infants with Type I SMA for 24 months, followed by an open-label extension. ?The primary objective of part two is to assess the efficacy of RG7916 at the selected dose over a 12-month treatment period.

•A trial in childhood onset (Type II/III) SMA patients, SUNFISH, is currently enrolling the dose escalation portion of the study.
•Commencement of the pivotal portion of either study will trigger a $20 mln milestone payment to co from Roche (RHHBY).

This was announced a while back, but PTC announced the initiation of the study today. This started in 2006, so hopefully things can move along to help the kids who are affected.

http://www.prnewswire.com/news-releases/ptc-therapeutics-announces-initiation-of-firefish-study-in-infant-type-i-sma-patients-300386262.html

$PTCT Day Trading Idea for November 14 https://goo.gl/BEAOQ0

PTCT bearish 11.30

no position just watching chart


















normal chart


log chart

* * $PTCT Video Chart 11-11-16 * *

Link to Video - click here to watch the technical chart video

good Volume

Yeah 2nd short here it's easier to see the short opportunities than it is the bounces. Everyone can make $$ on both sides of the coin here.

PTCT was a cash cow from pre market from $9.80 to over $11.00 missed that second dip because I was gone but sold all my shares at $11.10. GL

Nice bounce Time to short again $11.20 no brainer

Awesome short from $11+!

wow PM is nuts right now

Or Short

Well made quite the run today. Was a good one. Broke trend line now. Possible play later in the week. =D

Man did this take a hit today!

Approvals somewhere. Earnings were decent and they are moving forward, although the language in the portion about EMA wasn't exactly confidence inspiring, at least they are not blowing smoke. Guidance was conservative as well.

Up over 2% on a down day. Anyone bullish here?

... what catalyst would be needed to take this higher?

Ups And Downs In Biotech This Week: PTC Therapeutics, Puma Biotechnology and Nektar Therapeutics http://marketexclusive.com/ups-downs-biotech-week/34468/?icd1

Thank you and nice trade!

They'll do a 2nd level appeal to FDA like SRPT but not much hope. Plus they got bad news in Europe as well.

You can't short PTCT because it's on the 'no short' stock list so hopes of any type of short squeeze is out and it looks like all the institution holders are still unloading.

Just sold my $9 PUTS here @ $6.95 for 5x bagger but could be going back to $5s soon.

So is there any hope for PTCT going forward? Would love to swing trade this again hopefully from the 5's